Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.

Author: Akwaso MassaFélix, Asuka Akongo NgubaAndré, Betu KumesoVictor Kande, CamaraMamadou, CatusseJulie, DelhommeSophie, Embana MankiaraHugues, Fifi Nzeza BambuwuAimée, Ilunga Wa KyhiMédard, KalonjiWilfried Mutombo, Kaninda BadibabiLewis, Kasongo BonamaAugustin, Kavunga LukulaPapy, Kobo MuanzaVincent, Layba CamaraMariame, Mahenzi MbemboHélène, Makaya MayawulaJoseph, Mariero PhilemonPhyll, Mokilifi NganyonyiRicardo, Mulenge NasandhelErnest, Mutanda KalonjiSylvain, Mwamba MiakaErick, Ngolo TeteDigas, NusbaumerMorgane, PrêtreAdeline, RembrySandra, ScherrerBruno, SchneitterStefan, Strub-WourgaftNathalie, TarralAntoine, Valverde MordtOlaf

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study aims to assess the safety and efficacy of acoziborole in adult and adolescent patients with gambiense HAT, a late-stage form of human African trypanosomiasis.
Paper Details　
Original Abstract of the Article :
Human African trypanosomiasis caused by Trypanosoma brucei gambiense (gambiense HAT) in patients with late-stage disease requires hospital admission to receive nifurtimox-eflornithine combination therapy (NECT). Fexinidazole, the latest treatment that has been recommended by WHO, also requires syste...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033454/

データ提供：米国国立医学図書館（NLM）

Acoziborole: A Potential New Treatment for Human African Trypanosomiasis

Human African trypanosomiasis, also known as sleeping sickness, is a serious parasitic disease that affects millions of people worldwide. It's a formidable foe, often requiring hospitalization for treatment. This study explores the potential of a new drug, Acoziborole, as a treatment option for late-stage gambiense HAT. The researchers sought to assess the safety and efficacy of this drug in adult and adolescent patients.

Acoziborole: An Oasis in the Desert of Treatment Options

The study's findings suggest that Acoziborole could provide a valuable alternative to current treatments, which often require hospitalization and can be difficult to administer in regions with limited healthcare resources. This is a significant breakthrough, particularly for those living in remote areas with limited access to medical facilities. The study found that Acoziborole is safe and effective in treating gambiense HAT, offering a new beacon of hope for patients.

Dr.Camel's Conclusion

This research on Acoziborole is like discovering a hidden spring in the desert of sleeping sickness. It offers a promising new treatment option, particularly for those in underserved regions. The potential for a safer and more accessible treatment is truly a cause for celebration.

Date :
  1. Date Completed 2023-03-30
  2. Date Revised 2023-04-13
Further Info :

Pubmed ID

36460027

DOI: Digital Object Identifier

PMC10033454

Related Literature

Article Analysis
・Effects of eflornithine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.